Pfizer Inc (PFE)vsSanofi ADR (SNY)
PFE
Pfizer Inc
$25.68
-1.40%
HEALTHCARE · Cap: $150.92B
SNY
Sanofi ADR
$43.31
+0.30%
HEALTHCARE · Cap: $103.45B
Smart Verdict
WallStSmart Research — data-driven comparison
Pfizer Inc generates 34% more annual revenue ($63.32B vs $47.35B). SNY leads profitability with a 16.0% profit margin vs 11.8%. SNY appears more attractively valued with a PEG of 3.76. PFE earns a higher WallStSmart Score of 55/100 (C).
PFE
Buy55
out of 100
Grade: C
SNY
Buy51
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+29.4%
Fair Value
$37.48
Current Price
$25.68
$11.80 discount
Margin of Safety
+24.9%
Fair Value
$62.64
Current Price
$43.31
$19.33 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Strong operational efficiency at 31.6%
Large-cap with strong market position
Reasonable price relative to book value
Generating 2.2B in free cash flow
Reasonable price relative to book value
Large-cap with strong market position
Strong operational efficiency at 20.0%
Generating 1.7B in free cash flow
Areas to Watch
Weak financial health signals
Expensive relative to growth rate
Earnings declined 10.1%
ROE of 6.6% — below average capital efficiency
Expensive relative to growth rate
Earnings declined 11.7%
Comparative Analysis Report
WallStSmart ResearchBull Case : PFE
The strongest argument for PFE centers on Operating Margin, Market Cap, Price/Book.
Bull Case : SNY
The strongest argument for SNY centers on Price/Book, Market Cap, Operating Margin. Profitability is solid with margins at 16.0% and operating margin at 20.0%.
Bear Case : PFE
The primary concerns for PFE are Piotroski F-Score, PEG Ratio, EPS Growth.
Bear Case : SNY
The primary concerns for SNY are Return on Equity, PEG Ratio, EPS Growth.
Key Dynamics to Monitor
PFE profiles as a value stock while SNY is a mature play — different risk/reward profiles.
PFE carries more volatility with a beta of 0.30 — expect wider price swings.
SNY is growing revenue faster at 6.0% — sustainability is the question.
PFE generates stronger free cash flow (2.2B), providing more financial flexibility.
Bottom Line
PFE scores higher overall (55/100 vs 51/100). SNY offers better value entry with a 24.9% margin of safety. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Pfizer Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Pfizer Inc. is an American multinational pharmaceutical and biotechnology corporation headquartered on 42nd Street in Manhattan, New York City. The name of the company commemorates its co-founder, Charles Pfizer (1824-1906). Pfizer develops and produces medicines and vaccines for immunology, oncology, cardiology, endocrinology, and neurology. The company has several blockbuster drugs or products that each generate more than 1 billion USD in annual revenues.
Visit Website →Sanofi ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Sanofi, a healthcare company, is engaged in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. The company is headquartered in Paris, France.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?